Summary
Arkansas Blue Cross updated preferred and non-preferred drug lists for multiple specialty medications including cancer treatments, eye injections, and biosimilar drugs. Most changes take effect January 1, 2026, with one Brentuximab coverage update effective December 1, 2025.
Get alerts when payers change rules like this one
We check Arkansas Blue Cross Blue Shield and other payers every day and email you when a change matches your specialty and state.
Get Arkansas Blue Cross Blue Shield alertsPolicy Monitoring is free. No card required.
What to do
Action · 4 steps
01Before December 1, 2025: Update prior authorization processes for Brentuximab (Adcetris) with new coverage criteria for anaplastic large cell lymphoma and large B-cell lymphoma.
02Before January 1, 2026: Update billing system to reflect new preferred/non-preferred drug lists for Ustekinumab biosimilars, ophthalmic VEGF inhibitors, white blood cell growth factors, Rituximab, Trastuzumab, Eculizumab, and Infliximab.
03Verify patient insurance coverage and obtain prior authorization for non-preferred products.
04Claims may be denied without proper authorization.
Original notice
Policy Criteria Changes
assets.contentstack.io no longer serves this document. We saved a copy on Nov 7, 2026.
Related changes
See all Arkansas Blue Cross Blue Shield changes →Policy Criteria ChangesMediumEffective Nov 24, 2025 · Medical PolicyPolicy Criteria ChangesLowEffective Nov 15, 2025 · Medical PolicyPolicy Criteria ChangesMediumEffective Nov 15, 2025 · Medical PolicyPolicy Criteria ChangesMediumEffective Nov 15, 2025 · Medical PolicyBrowse every Arkansas Blue Cross Blue Shield change in the policy list